Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) was downgraded by Zacks  from a “acquire” ranking to a “hold” score in a research note issued to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on finding and also developing little molecule medicine candidates to deal with cancer. The Company‘s items under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research analysts likewise recently discussed the business. Noble Financial reissued a “purchase” ranking and also provided a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and established a “purchase” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving average price of $2.90 and also a two-hundred day relocating average price of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) incomes per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as an unfavorable net margin of 8,294.27%. The firm had income of $0.06 million during the quarter, contrasted to the consensus price quote of $0.06 million. During the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will publish -1.18 EPS for the existing year.

A number of hedge funds have lately bought and sold shares of ONTX. GSA Funding Partners LLP got a new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Management LP got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional investors have 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the identification and also development of oncology therapeutics. It concentrates on discovering as well as developing small molecule medicine candidates to treat cancer cells. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For additional information concerning research offerings from Zacks Investment Research, browse through Zacks.com.

This instant news alert was produced by narrative science innovation and also monetary data from Market in order to offer readers with the fastest and also most accurate coverage. This story was reviewed by Market’s editorial group prior to magazine. 



Before you think about Onconova Therapeutics, you’ll intend to hear this.

Market keeps an eye on Wall Street’s premier and also ideal carrying out research experts and also the stocks they advise to their clients on a daily basis. Market has actually determined the five stocks that top analysts are silently whispering to their clients to purchase currently prior to the wider market catches on … and also Onconova Therapeutics had not been on the checklist.

While Onconova Therapeutics currently has a “Buy” ranking among experts, premier experts believe these five stocks are much better acquires.